AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16537213 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control (contralateral thigh)
Number of subjects: 20
Study 11727130 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal preperitoneal (TAPP) hernia repair
Number of subjects: 100
Study 11727130 — intervention group
Group type: COMPARATOR
Intervention: Shouldice hernia repair
Number of subjects: 100
Study 11727130 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPP hernia repair
Number of subjects: 100
Study 9132344 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LAE)
Number of subjects: 0
Study 9132344 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OAE)
Number of subjects: 0
Study 7945629 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg intracervical PgE2 gel
Number of subjects: 960
Study 2908030 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205-502 (0.05 to 0.15 mg once daily for 6 months)
Number of subjects: 24
Study 2908030 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205-502
Number of subjects: 24
Study 31828755 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-controlled ventilation (FCV)
Number of subjects: 20
Study 31828755 — intervention group
Group type: COMPARATOR
Intervention: Baseline ventilation (BL)
Number of subjects: 20
Study 31828755 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 20
Study 31479717 — intervention group
Group type: EXPERIMENTAL
Intervention: WW + Tyr (white wine plus 25 mg Tyr capsule)
Number of subjects: 33
Study 28614675 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Value-Based Purchasing (HVBP) program
Number of subjects: 1364
Study 25580916 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) plus risperidone
Number of subjects: 40
Study 25580916 — intervention group
Group type: COMPARATOR
Intervention: Risperidone plus placebo
Number of subjects: 40
Study 23425772 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 fatty acids (1440 mg/day, n=8)
Number of subjects: 18
Study 23425772 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 18
Study 21035980 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg loading dose of warfarin
Number of subjects: 0
Study 21035980 — intervention group
Group type: COMPARATOR
Intervention: 5 mg dose of warfarin
Number of subjects: 0
Study 21035980 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (1.5 mg/kg per day)
Number of subjects: 0
Study 19380898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 41
Study 19380898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin
Number of subjects: 41
Study 19380898 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 41
Study 16769916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy
Number of subjects: 210
Study 16769916 — intervention group
Group type: COMPARATOR
Intervention: Moderate lipid-lowering therapy
Number of subjects: 210
Study 15207210 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 32
Study 15207210 — intervention group
Group type: COMPARATOR
Intervention: No pilocarpine (Control)
Number of subjects: 32
Study 11223900 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive AIDS education video intervention
Number of subjects: 0
Study 11223900 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9141579 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Number of subjects: 150
Study 9141579 — intervention group
Group type: COMPARATOR
Intervention: Cardiotocography
Number of subjects: 150
Study 7835816 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus cyclophosphamide
Number of subjects: 0
Study 7835816 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 0
Study 7835816 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxol plus cisplatin
Number of subjects: 0
Study 3296159 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (5000 I.U. subcutaneous injection once a day for 5 consecutive weekdays)
Number of subjects: 20
Study 3296159 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous injection once a day for 5 consecutive weekdays)
Number of subjects: 20
Study 31982480 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (Bydureon), 12 weeks treatment
Number of subjects: 24
Study 29887321 — intervention group
Group type: EXPERIMENTAL
Intervention: New vaccines added to the early childhood vaccine schedule (4 new antigens); assessed from 2006 to 2016.
Number of subjects: 3515
Study 29887321 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines included in the schedule; assessed in 2016.
Number of subjects: 3515
Study 29887321 — intervention group
Group type: EXPERIMENTAL
Intervention: New vaccines introduced; assessed within 2 years of their introduction.
Number of subjects: 3515
Study 29887321 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete vaccine status by 24 months of age; associated factors.
Number of subjects: 3515
Study 26541692 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional remediation
Number of subjects: 3
Study 26541692 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 3
Study 26541692 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 3
Study 26573910 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic tests (RDTs) for malaria introduced in registered drug shops
Number of subjects: 0
Study 23153175 — intervention group
Group type: EXPERIMENTAL
Intervention: InnoScope
Number of subjects: 25
Study 23153175 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 25
Study 22047971 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ocrelizumab
Number of subjects: 220
Study 22047971 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg ocrelizumab
Number of subjects: 220
Study 22047971 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1a
Number of subjects: 220
Study 22047971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 19168445 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (gonadotrophin-releasing hormone analog) for 24 weeks
Number of subjects: 43
Study 19168445 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (androgen receptor blocker) for 24 weeks
Number of subjects: 43
Study 19168445 — intervention group
Group type: COMPARATOR
Intervention: Untreated men (control group)
Number of subjects: 43
Study 16842666 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril + spironolactone (20 mg/d)
Number of subjects: 130
Study 16842666 — intervention group
Group type: COMPARATOR
Intervention: enalapril
Number of subjects: 130
Study 16842666 — intervention group
Group type: COMPARATOR
Intervention: anti‐hypertensive drugs not directly affecting RAAS (group C)
Number of subjects: 130
Study 15354041 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Training Group (WTG)
Number of subjects: 22
Study 15354041 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training Group (CTG)
Number of subjects: 22
Study 15354041 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 22
Study 11299036 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent tablets of chloroquine phosphate 300 mg
Number of subjects: 60
Study 11299036 — intervention group
Group type: COMPARATOR
Intervention: Uncoated tablets of chloroquine phosphate 300 mg
Number of subjects: 60
Study 7614213 — intervention group
Group type: EXPERIMENTAL
Intervention: ENDEX apex locator
Number of subjects: 61
Study 7614213 — intervention group
Group type: COMPARATOR
Intervention: RCM Mark II apex locator
Number of subjects: 61
Study 2758732 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nalbuphine (0.2 mg/kg) in children (group I)
Number of subjects: 32
Study 2758732 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nalbuphine (10 mg) in healthy volunteers (group II)
Number of subjects: 32
Study 2758732 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nalbuphine (30 mg) in healthy volunteers (group II)
Number of subjects: 32
Study 2758732 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nalbuphine (10 mg) in elderly patients (group III)
Number of subjects: 32
Study 2758732 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nalbuphine (30 mg) in elderly patients (group III)
Number of subjects: 32
Study 931391 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin
Number of subjects: 0
Study 931391 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole
Number of subjects: 0
Study 931391 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole
Number of subjects: 0
Study 931391 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiabendazole
Number of subjects: 0
Study 30151798 — intervention group
Group type: EXPERIMENTAL
Intervention: IRE-NK group (n=18)
Number of subjects: 40
Study 30151798 — intervention group
Group type: COMPARATOR
Intervention: IRE group (n=22)
Number of subjects: 40
Study 29082904 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-suxamethonium
Number of subjects: 66
Study 29082904 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 66
Study 26132725 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive framing condition (support)
Number of subjects: 0
Study 26132725 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative framing condition (oppose)
Number of subjects: 0
Study 24310818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually aggressive men
Number of subjects: 78
Study 24310818 — intervention group
Group type: COMPARATOR
Intervention: Non-aggressive men
Number of subjects: 78
Study 22579429 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 4
Study 22579429 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 4
Study 19185975 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar TURP
Number of subjects: 70
Study 19185975 — intervention group
Group type: COMPARATOR
Intervention: Monopolar TURP
Number of subjects: 70
Study 17565162 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of processing training program
Number of subjects: 0
Study 15766303 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/day
Number of subjects: 138
Study 15766303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day
Number of subjects: 138
Study 12475661 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyography‐assisted biofeedback training
Number of subjects: 30
Study 12475661 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT) alone
Number of subjects: 30
Study 9535664 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast cereal fortified with 127 microg of folic acid daily
Number of subjects: 75
Study 9535664 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast cereal fortified with 499 microg of folic acid daily
Number of subjects: 75
Study 9535664 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast cereal fortified with 665 microg of folic acid daily
Number of subjects: 75
Study 9180980 — intervention group
Group type: EXPERIMENTAL
Intervention: TOF at 0.05 Hz
Number of subjects: 40
Study 9180980 — intervention group
Group type: COMPARATOR
Intervention: TOF at 0.08 Hz
Number of subjects: 40
Study 1918422 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 16
Study 1918422 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine
Number of subjects: 16
Study 1918422 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 16
Study 6122848 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 orally
Number of subjects: 739
Study 6122848 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin intravenously
Number of subjects: 739
Study 6122848 — intervention group
Group type: EXPERIMENTAL
Intervention: Demoxytocin buccally
Number of subjects: 739
Study 6122848 — intervention group
Group type: COMPARATOR
Intervention: No oxytocics (after primary amniotomy)
Number of subjects: 739
Study 30862635 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol with additional use of electrical impedance tomography (EIT)
Number of subjects: 2
Study 30862635 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salbutamol without additional use of electrical impedance tomography (EIT)
Number of subjects: 2
Study 28536463 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea containing 200mg EGCG
Number of subjects: 50
Study 28536463 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE)
Number of subjects: 50
Study 28536463 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated EGCG
Number of subjects: 50
Study 28536463 — intervention group
Group type: COMPARATOR
Intervention: Control (NMD)
Number of subjects: 50
Study 27611433 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Physical Therapy (RPT)
Number of subjects: 27
Study 27611433 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy children)
Number of subjects: 27
Study 24885136 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone block grafts (AUBB)
Number of subjects: 31
Study 24885136 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic bone block grafts (ABB)
Number of subjects: 31
Study 21777974 — intervention group
Group type: COMPARATOR
Intervention: 14-day standard therapy (lansoprazole, amoxicillin, clarithromycin)
Number of subjects: 1463
Study 21777974 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day concomitant therapy (lansoprazole, amoxicillin, clarithromycin, metronidazole)
Number of subjects: 1463
Study 21777974 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (5 days of lansoprazole and amoxicillin followed by 5 days of lansoprazole, clarithromycin, and metronidazole)
Number of subjects: 1463
Study 19565743 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Number of subjects: 0
Study 19565743 — intervention group
Group type: COMPARATOR
Intervention: Positive control methods
Number of subjects: 0
Study 17565935 — intervention group
Group type: EXPERIMENTAL
Intervention: verum 1 (nondenaturated isolated soy protein)
Number of subjects: 120
Study 17565935 — intervention group
Group type: EXPERIMENTAL
Intervention: verum 2 (conventional isolated soy protein)
Number of subjects: 120
Study 17565935 — intervention group
Group type: COMPARATOR
Intervention: placebo (milk protein)
Number of subjects: 120
Study 15060437 — intervention group
Group type: EXPERIMENTAL
Intervention: GW433908 1395 mg QD + RTV 200 mg QD
Number of subjects: 0
Study 15060437 — intervention group
Group type: EXPERIMENTAL
Intervention: GW433908 700 mg BID + RTV 100 mg BID
Number of subjects: 0
Study 15060437 — intervention group
Group type: EXPERIMENTAL
Intervention: GW433908 1395 mg QD + RTV 300 mg QD
Number of subjects: 0
Study 15060437 — intervention group
Group type: COMPARATOR
Intervention: EFV 600 mg QD with GW433908 + RTV regimen
Number of subjects: 0
Study 15060437 — intervention group
Group type: COMPARATOR
Intervention: EFV 600 mg QD with GW433908 1395 mg QD + RTV 200 mg QD
Number of subjects: 0
Study 11666098 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 15
Study 9495407 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine
Number of subjects: 51
Study 9495407 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine
Number of subjects: 51
Study 8834668 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose antacids (bismuth subnitrate - Gastrin and Wikalina)
Number of subjects: 169
Study 8834668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 169
Study 8834668 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate
Number of subjects: 169
Study 8834668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 2642979 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal (710 kcal)
Number of subjects: 9
Study 2642979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucagon (40 micrograms/min)
Number of subjects: 9
Study 2642979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vasopressin (0.2 units/min)
Number of subjects: 9
Study 1103919 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoctamine
Number of subjects: 0
Study 1103919 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 1103919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1103919 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (in animal experiments)
Number of subjects: 0
Study 31811456 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D/HD monitor
Number of subjects: 66
Study 31811456 — intervention group
Group type: COMPARATOR
Intervention: 2-D/4K monitor
Number of subjects: 66
Study 31811456 — intervention group
Group type: COMPARATOR
Intervention: 2-D/HD monitor
Number of subjects: 66
Study 30570198 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Based Learning (TBL) on 'organ function tests'
Number of subjects: 100
Study 30570198 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture on 'organ function tests'
Number of subjects: 100
Study 30570198 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Based Learning (TBL)
Number of subjects: 100
Study 27320010 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 87
Study 27320010 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 87
Study 25998278 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced supported employment plus the Thinking Skills for Work program
Number of subjects: 107
Study 25998278 — intervention group
Group type: COMPARATOR
Intervention: Enhanced supported employment only
Number of subjects: 107
Study 24830730 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 24
Study 22005659 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 98
Study 22005659 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 98
Study 22005659 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg
Number of subjects: 98
Study 22005659 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (all doses)
Number of subjects: 98
Study 18356831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine 0.125 mg
Number of subjects: 968
Study 18356831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine 0.25 mg
Number of subjects: 968
Study 18356831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine 0.5 mg
Number of subjects: 968
Study 18356831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine 1.0 mg
Number of subjects: 968
Study 18356831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968
Study 18356831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine (all doses combined)
Number of subjects: 968
Study 18356831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine (0.25 mg and above)
Number of subjects: 968
Study 17349164 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v group
Number of subjects: 88
Study 17349164 — intervention group
Group type: COMPARATOR
Intervention: i.m group
Number of subjects: 88
Study 17349164 — intervention group
Group type: EXPERIMENTAL
Intervention: domino group
Number of subjects: 88
Study 12900815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral heme iron
Number of subjects: 37
Study 10698808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 154
Study 10698808 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 154
Study 10698808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 9216958 — intervention group
Group type: EXPERIMENTAL
Intervention: Tr (trained)
Number of subjects: 22
Study 9216958 — intervention group
Group type: COMPARATOR
Intervention: UT (untrained)
Number of subjects: 22
Study 8153036 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational training program combining self-management training and cognitive behaviour therapy; ten 1-hour sessions over 18 months.
Number of subjects: 112
Study 8153036 — intervention group
Group type: COMPARATOR
Intervention: Control groups (two control groups); no specific intervention details provided.
Number of subjects: 112
Study 2869638 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft gelatin capsule of temazepam 20 mg
Number of subjects: 60
Study 2869638 — intervention group
Group type: COMPARATOR
Intervention: Tablet of temazepam 20 mg
Number of subjects: 60
Study 30409178 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle turbinectomy
Number of subjects: 16
Study 27339057 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with fractional Er:YAG laser and 5% amorolfine lacquer (group 1)
Number of subjects: 9
Study 27339057 — intervention group
Group type: COMPARATOR
Intervention: Amorolfine lacquer only (group 2)
Number of subjects: 9
Study 24943856 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 90
Study 24943856 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg
Number of subjects: 90
Study 24943856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 23156940 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic Movement Therapy (RMT)
Number of subjects: 58
Study 23156940 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 58
Study 20386330 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap and water washing
Number of subjects: 45
Study 20386330 — intervention group
Group type: COMPARATOR
Intervention: No-rinse cleanser
Number of subjects: 45
Study 18271231 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Xuanzhong (GB 39) and Ashi points for 30 minutes
Number of subjects: 60
Study 18271231 — intervention group
Group type: COMPARATOR
Intervention: Bezoxazocine injection, 20 mg once, three times per day
Number of subjects: 60
Study 15494707 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperprolinemia
Number of subjects: 434